Florian Lipsmeier
Overview
Explore the profile of Florian Lipsmeier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
692
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kriara L, Zanon M, Lipsmeier F, Lindemann M
Physiol Meas
. 2023 Nov;
44(12).
PMID: 38029439
Physiological sensor data (e.g. photoplethysmograph) is important for remotely monitoring patients' vital signals, but is often affected by measurement noise. Existing feature-based models for signal cleaning can be limited as...
2.
Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test
Graves J, Elantkowski M, Zhang Y, Dondelinger F, Lipsmeier F, Bernasconi C, et al.
JMIR Form Res
. 2023 Oct;
7:e46521.
PMID: 37782540
Background: The development of touchscreen-based assessments of upper extremity function could benefit people with multiple sclerosis (MS) by allowing convenient, quantitative assessment of their condition. The Pinching Test forms a...
3.
Perumal T, Wolf D, Berchtold D, Pointeau G, Zhang Y, Cheng W, et al.
Neuromuscul Disord
. 2023 Sep;
33(11):845-855.
PMID: 37722988
Spinal muscular atrophy (SMA) is characterized by progressive muscle weakness and paralysis. Motor function is monitored in the clinical setting using assessments including the 32-item Motor Function Measure (MFM-32), but...
4.
OSullivan J, Bogaarts G, Schoenenberger P, Tillmann J, Slater D, Mesgarani N, et al.
Sci Rep
. 2023 Jun;
13(1):10270.
PMID: 37355730
Challenges in social communication is one of the core symptom domains in autism spectrum disorder (ASD). Novel therapies are under development to help individuals with these challenges, however the ability...
5.
Chen O, Lipsmeier F, Phan H, Dondelinger F, Creagh A, Gossens C, et al.
IEEE J Biomed Health Inform
. 2023 May;
27(7):3633-3644.
PMID: 37134029
Personalized longitudinal disease assessment is central to quickly diagnosing, appropriately managing, and optimally adapting the therapeutic strategy of multiple sclerosis (MS). It is also important for identifying idiosyncratic subject-specific disease...
6.
Creagh A, Dondelinger F, Lipsmeier F, Lindemann M, De Vos M
IEEE Open J Eng Med Biol
. 2022 Dec;
3:202-210.
PMID: 36578776
Smartphone and wearable devices may act as powerful tools to remotely monitor physical function in people with neurodegenerative and autoimmune diseases from out-of-clinic environments. Detection of progression onset or worsening...
7.
Graves J, Ganzetti M, Dondelinger F, Lipsmeier F, Belachew S, Bernasconi C, et al.
Ann Clin Transl Neurol
. 2022 Dec;
10(2):166-180.
PMID: 36563127
Objective: To validate the smartphone sensor-based Draw a Shape Test - a part of the Floodlight Proof-of-Concept app for remotely assessing multiple sclerosis-related upper extremity impairment by tracing six different...
8.
Ganzetti M, Graves J, Holm S, Dondelinger F, Midaglia L, Gaetano L, et al.
J Neurol
. 2022 Dec;
270(3):1624-1636.
PMID: 36469103
Background: A study was undertaken to evaluate remote monitoring via smartphone sensor-based tests in people with multiple sclerosis (PwMS). This analysis aimed to explore regional neural correlates of digital measures...
9.
Holm S, Wolfer A, Pointeau G, Lipsmeier F, Lindemann M
Heliyon
. 2022 Sep;
8(8):e10259.
PMID: 36082322
Background: In this systematic review we sought to characterize practice effects on traditional in-clinic or digital performance outcome measures commonly used in one of four neurologic disease areas (multiple sclerosis;...
10.
Pagano G, Taylor K, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al.
N Engl J Med
. 2022 Aug;
387(5):421-432.
PMID: 35921451
Background: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease....